You are about to leave the Clinical Value website now.

Cancel

Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosis

Quick Summary

Prothrombin induced by vitamin K absence-II (PIVKA-II) is a serum biomarker linked to hepatocellular carcinoma (HCC), showing superiority to alpha-fetoprotein (AFP) for early disease detection. This study assesses the clinical and analytical performance of the Elecsys® PIVKA-II immunoassay in diagnosing HCC and evaluate PIVKA-II’s technical performance.

You May Also Like

13 February 2024

The Pursuit for Better Patient Outcomes – Innovating HCC Management at Siriraj Hospital

Read More
7 November 2023

Value and Challenges for Precision Oncology Realisation in Real World Practice

Read More

SHARE

Be the first to receive updates, event opportunities, and thought leadership insights.